Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul;45(9):1497-1508.
doi: 10.1007/s00259-018-4039-7. Epub 2018 Apr 27.

Clinical utility of FDG-PET for the clinical diagnosis in MCI

Javier Arbizu  1 , Cristina Festari  2   3 , Daniele Altomare  2   3 , Zuzana Walker  4 , Femke Bouwman  5 , Jasmine Rivolta  2 , Stefania Orini  6 , Henryk Barthel  7 , Federica Agosta  8 , Alexander Drzezga  9 , Peter Nestor  10   11 , Marina Boccardi  12   13 , Giovanni Battista Frisoni  2   14   15 , Flavio Nobili  16 ; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders
Affiliations
Free article
Review

Clinical utility of FDG-PET for the clinical diagnosis in MCI

Javier Arbizu et al. Eur J Nucl Med Mol Imaging. 2018 Jul.
Free article

Abstract

Purpose: We aim to report the quality of accuracy studies investigating the utility of [18F]fluorodeoxyglucose (FDG)-PET in supporting the diagnosis of prodromal Alzheimer's Disease (AD), frontotemporal lobar degeneration (FTLD) and prodromal dementia with Lewy bodies (DLB) in mild cognitive impairment (MCI) subjects, and the corresponding recommendations made by a panel of experts.

Methods: Seven panellist, four from the European Association of Nuclear Medicine, and three from the European Academy of Neurology, produced recommendations taking into consideration the incremental value of FDG-PET, as added on clinical-neuropsychological examination, to ascertain the aetiology of MCI (AD, FTLD or DLB). A literature search using harmonized population, intervention, comparison, and outcome (PICO) strings was performed, and an evidence assessment consistent with the European Federation of Neurological Societies guidance was provided. The consensual recommendation was achieved based on Delphi rounds.

Results: Fifty-four papers reported the comparison of interest. The selected papers allowed the identification of FDG patterns that characterized MCI due to AD, FTLD and DLB. While clinical outcome studies supporting the diagnosis of MCI due to AD showed varying accuracies (ranging from 58 to 100%) and varying areas under the receiver-operator characteristic curves (0.66 to 0.97), no respective data were identified for MCI due to FTLD or for MCI due to DLB. However, the high negative predictive value of FDG-PET and the existence of different disease-specific patterns of hypometabolism support the consensus recommendations for the clinical use of this imaging technique in MCI subjects.

Conclusions: FDG-PET has clinical utility on a fair level of evidence in detecting MCI due to AD. Although promising also in detecting MCI due to FTLD and MCI due to DLB, more research is needed to ultimately judge the clinical utility of FDG-PET in these entities.

Keywords: Alzheimer’s disease; Dementia with Lewy bodies; Differential diagnosis; FDG-PET; Frontotemporal lobar degeneration; MCI.

PubMed Disclaimer

References

    1. Neurobiol Aging. 2015 Nov;36(11):3108-3115 - PubMed
    1. Neuroimage Clin. 2014 Dec 05;7:187-94 - PubMed
    1. J Nucl Med. 2012 Apr;53(4):592-600 - PubMed
    1. Alzheimers Dement. 2016 Mar;12(3):292-323 - PubMed
    1. Neurology. 2003 Apr 22;60(8):1374-7 - PubMed

MeSH terms

Substances